79 related articles for article (PubMed ID: 35700416)
1. Medication Adherence Among Adults With Comorbid Chronic Conditions Initiating Oral Anticancer Agent Therapy for Multiple Myeloma.
Gatwood J; Dashputre A; Rajpurohit A; Gatwood K; Mackler E; Wallace L; Farris K; Rizvi-Toner A; Farley J
JCO Oncol Pract; 2022 Sep; 18(9):e1475-e1483. PubMed ID: 35700416
[TBL] [Abstract][Full Text] [Related]
2. Impact of initiating oral anticancer agents for leukemia on adherence to medications for multiple chronic conditions.
Gatwood J; Dashputre A; Rajpurohit A; Gatwood K; Mackler E; Wallace L; Farris K; Rizvi-Toner A; Farley J
J Oncol Pharm Pract; 2024 Mar; 30(2):342-353. PubMed ID: 37113049
[TBL] [Abstract][Full Text] [Related]
3. Impact of oral oncolytic initiation on medication adherence for pre-existing comorbid chronic conditions.
Dashputre AA; S Gatwood K; Schmidt J; Gatwood J
J Oncol Pharm Pract; 2020 Jun; 26(4):835-845. PubMed ID: 31575355
[TBL] [Abstract][Full Text] [Related]
4. Medication Adherence, Health Care Utilization, and Costs Among Patients Initiating Oral Oncolytics for Multiple Myeloma or Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma.
Dashputre AA; Gatwood KS; Gatwood J
J Manag Care Spec Pharm; 2020 Feb; 26(2):186-196. PubMed ID: 32011965
[TBL] [Abstract][Full Text] [Related]
5. Oral Anticancer Agent (OAA) Adherence and Survival in Elderly Patients With Metastatic Renal Cell Carcinoma (mRCC).
Dinan MA; Wilson LE; Greiner MA; Spees LP; Pritchard JE; Zhang T; Kaye D; George D; Scales CD; Baggett CD; Gross CP; Leapman MS; Wheeler SB
Urology; 2022 Oct; 168():129-136. PubMed ID: 35878815
[TBL] [Abstract][Full Text] [Related]
6. Patient, provider, and hospital factors associated with oral anti-neoplastic agent initiation and adherence in older patients with metastatic renal cell carcinoma.
Kaye DR; Wilson LE; Greiner MA; Spees LP; Pritchard JE; Zhang T; Pollack CE; George D; Scales CD; Baggett CD; Gross CP; Leapman MS; Wheeler SB; Dinan MA
J Geriatr Oncol; 2022 Jun; 13(5):614-623. PubMed ID: 35125336
[TBL] [Abstract][Full Text] [Related]
7. Provider- and patient-level predictors of oral anticancer agent initiation and adherence in patients with metastatic renal cell carcinoma.
Spees LP; Wheeler SB; Jackson BE; Baggett CD; Wilson LE; Greiner MA; Kaye DR; Zhang T; George D; Scales CD; Pritchard JE; Leapman M; Gross CP; Dinan MA
Cancer Med; 2021 Oct; 10(19):6653-6665. PubMed ID: 34480518
[TBL] [Abstract][Full Text] [Related]
8. Association between cognitive impairment and oral anticancer agent use in older patients with metastatic renal cell carcinoma.
Pritchard JE; Wilson LE; Miller SM; Greiner MA; Cohen HJ; Kaye DR; Zhang T; Dinan MA
J Am Geriatr Soc; 2022 Aug; 70(8):2330-2343. PubMed ID: 35499667
[TBL] [Abstract][Full Text] [Related]
9. Implementation of a model integrating primary and oncology pharmacists' care for patients taking oral anticancer agents (OAA).
Farris KB; Cadwallader T; Farley J; Gatwood K; Mackler E; Gatwood J
Explor Res Clin Soc Pharm; 2022 Sep; 7():100163. PubMed ID: 35957656
[TBL] [Abstract][Full Text] [Related]
10. Predictors of adherence to concomitant antihypertensive and lipid-lowering medications in older adults: a retrospective, cohort study.
Chapman RH; Petrilla AA; Benner JS; Schwartz JS; Tang SS
Drugs Aging; 2008; 25(10):885-92. PubMed ID: 18808213
[TBL] [Abstract][Full Text] [Related]
11. Medication Adherence, Health Care Utilization, and Spending Among Privately Insured Adults With Chronic Conditions in the United States, 2010-2016.
Gillespie CW; Morin PE; Tucker JM; Purvis L
Am J Med; 2020 Jun; 133(6):690-704.e19. PubMed ID: 31987798
[TBL] [Abstract][Full Text] [Related]
12. Treatment Patterns, Health Care Resource Utilization, and Spending in Medicaid Beneficiaries Initiating Second-generation Long-acting Injectable Agents Versus Oral Atypical Antipsychotics.
Pilon D; Tandon N; Lafeuille MH; Kamstra R; Emond B; Lefebvre P; Joshi K
Clin Ther; 2017 Oct; 39(10):1972-1985.e2. PubMed ID: 28919292
[TBL] [Abstract][Full Text] [Related]
13. Treatment discontinuation of long-acting injectables or oral atypical antipsychotics among Medicaid recipients with schizophrenia.
Song X; El Khoury AC; Brouillette M; Smith D; Joshi K
J Med Econ; 2019 Nov; 22(11):1105-1112. PubMed ID: 31062998
[No Abstract] [Full Text] [Related]
14. Impact of provider mailings on medication adherence by Medicare Part D members.
Borah BJ; Qiu Y; Shah ND; Gleason PP
Healthc (Amst); 2016 Sep; 4(3):207-16. PubMed ID: 27637828
[TBL] [Abstract][Full Text] [Related]
15. Patterns and Predictors of Oral Anticancer Agent Use in Diverse Patients With Metastatic Renal Cell Carcinoma.
Wheeler SB; Spees LP; Jackson BE; Baggett CD; Wilson LE; Greiner MA; Kaye DR; Zhang T; George D; Scales CD; Pritchard JE; Dinan MA
JCO Oncol Pract; 2021 Dec; 17(12):e1895-e1904. PubMed ID: 34138665
[TBL] [Abstract][Full Text] [Related]
16. Adherence to Maintenance Medications among Older Adults with Chronic Obstructive Pulmonary Disease. The Role of Depression.
Albrecht JS; Park Y; Hur P; Huang TY; Harris I; Netzer G; Lehmann SW; Langenberg P; Khokhar B; Wei YJ; Moyo P; Simoni-Wastila L
Ann Am Thorac Soc; 2016 Sep; 13(9):1497-504. PubMed ID: 27332765
[TBL] [Abstract][Full Text] [Related]
17. Association between adherence with oral anticancer medications and short-term health care resource utilization: A 2010-2018 claims-based analysis.
Vyas A; Parikh MA; Campbell PJ; Green A; Westrich K; Kogut S
J Manag Care Spec Pharm; 2024 Apr; 30(4):326-335. PubMed ID: 38241280
[TBL] [Abstract][Full Text] [Related]
18. A comparison of treatment patterns, healthcare resource utilization, and costs among young adult Medicaid beneficiaries with schizophrenia treated with paliperidone palmitate or oral atypical antipsychotics in the US.
Manjelievskaia J; Amos TB; El Khoury AC; Vlahiotis A; Cole A; Juneau P
J Med Econ; 2018 Dec; 21(12):1221-1229. PubMed ID: 30238806
[TBL] [Abstract][Full Text] [Related]
19. How adverse events and permanent medication stoppages affect changes in patients' beliefs about oral antineoplastic agents.
Marshall VK; Given CW; Sikorskii A; Given BA; Lehto RH
Support Care Cancer; 2020 Jun; 28(6):2589-2596. PubMed ID: 31529159
[TBL] [Abstract][Full Text] [Related]
20. Lower risk of major cardiovascular events associated with adherence to colesevelam HCI.
Ye X; Qian C; Liu J; St Peter WL
Pharmacotherapy; 2013 Oct; 33(10):1062-70. PubMed ID: 23798059
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
